The Center for Biosimilars® recaps the top news for the week of September 10, 2018.
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of September 10.
Number 5: While biosimilar filgrastim and biosimilar pegfilgrastim are effective in reducing the incidence of neutropenia, adverse events were shown in a recent study to be higher in patients who receive pegfilgrastim.
Number 4: Xbrane Biopharma has announced its intention to shift its focus from generic drugs to biosimilars.
Number 3: Newly published study results show that switching to Retacrit was noninferior to continuing treatment with Epogen.
Number 2: The United Kingdom is hoping to bring more biosimilar developers’ phase 3 trials to the nation’s National Health Service.
Number 1: The FDA’s Oncologic Drugs Advisory Committee will meet next month to discuss Celltrion’s rituximab biosimilar.
Finally, last week, our e-newsletter asked whether you think that biosimilar should be approved without the need for phase 3 studies.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.